Open Orphan (ORPH)
is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and is actively involved in the fight against COVID-19.
Shield Therapeutics (STX)
Shield is a commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Group’s lead product, Feraccru®/Accrufer® is approved for the treatment of iron deficiency in adults in the EU, USA and Switzerland. In Europe it is marketed as Feraccru® by Norgine and in the USA the product will be marketed as Accrufer®. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co. Ltd for the development and commercialisation of Feraccru®/Accrufer® in China.
Silence Therapeutics (SLN)
Silence Therapeutics is a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases.